Key Insights

Highlights

Success Rate

89% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

4.3%

1 terminated out of 23 trials

Success Rate

88.9%

+2.3% vs benchmark

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

38%

3 of 8 completed with results

Key Signals

3 with results89% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (7)
Early P 1 (2)
P 1 (1)
P 2 (2)
P 3 (2)

Trial Status

Completed8
Recruiting7
Not Yet Recruiting5
Active Not Recruiting1
Terminated1
Enrolling By Invitation1

Trial Success Rate

88.9%

Benchmark: 86.6%

Based on 8 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07237516Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07337902Not ApplicableRecruitingPrimary

Comparing Over the Counter Pain Medicines for Discomfort in Crohn's Disease (AVID-CD)

NCT07680283Not ApplicableRecruitingPrimary

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

NCT07671872Not ApplicableNot Yet Recruiting

Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease

NCT07636304Early Phase 1Enrolling By Invitation

VIBRANT-IBD: Brain Effects of Non-Invasive Vagus Nerve Stimulation in IBD Remission

NCT07630883Not Yet RecruitingPrimary

A Pilot Study: Micro and NanoPlastics in Association With Crohn's Disease

NCT07590271Not Yet Recruiting

Research on the Whole Process of AI Intelligent Management System for the Diagnosis and Treatment of Inflammatory Bowel Diseases

NCT04779320Phase 3RecruitingPrimary

A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

NCT07524244Not ApplicableRecruiting

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

NCT07528040Not Yet RecruitingPrimary

An Observational, Multicenter Study to Evaluate the Effectiveness of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection

NCT07522528Not ApplicableRecruitingPrimary

Biologics and Paediatric Enteral Nutrition in Crohn's Disease Study

NCT04524611Phase 3Active Not RecruitingPrimary

Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

NCT07309744Early Phase 1Not Yet Recruiting

Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease

NCT07078994Phase 2RecruitingPrimary

Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease

NCT02782663Phase 2CompletedPrimary

A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease

NCT04089514Completed

A Real-world Study of Imraldi® Use

NCT04271748Not ApplicableCompletedPrimary

The Impact of Time Restricted Feeding in Crohn's Disease

NCT02775656Terminated

UCB Cimzia Pregnancy Follow-up Study

NCT03801928Completed

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT02108821Phase 1Completed

Fecal Microbiota Transplantation in Pediatric Patients

Scroll to load more

Research Network

Activity Timeline